Free Alerts   Login
Health Care › Surgical & Medical Instruments & Apparatus

CVRX Stock Price Correlated With CVRx Financials

CVRX Stock Price vs. Quarterly
CVRX
Income Statement
Cash Flow
Balance Sheet

CVRX Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

CVRX Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

CVRX Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Johnson & Johnson
3,495,575 sh
 
$109,901
Nea Management Company
2,370,542 sh
 
$74,530
Blackrock.
803,434 sh
72,511 sh
10%
$25,259
$14,170
Lord, Abbett & Co.
774,670 sh
305,597 sh
65%
$25
$18
Vanguard Group
562,592 sh
12,564 sh
2%
$17,688
$9,344
Balyasny Asset Management
407,008 sh
-268,012 sh
-40%
$12,796
$2,556
Emerald Advisers
404,389 sh
-96,684 sh
-19%
$12,714
$5,113
Emerald Mutual Fund Advisers Trust
329,081 sh
-101,763 sh
-24%
$10,346
$3,810
Archon Capital Management
285,517 sh
285,517 sh
NEW
$8,977
$8,977
Geode Capital Management
249,543 sh
13,510 sh
6%
$7,846
$4,265
Parkman Healthcare Partners
240,000 sh
99,237 sh
70%
$7,546
$5,373
State Street
202,257 sh
-321,058 sh
-61%
$6,359
-$1,580
Silvercrest Asset Management Group
148,770 sh
148,770 sh
NEW
$4,677
$4,677
Caption Management
Call options for 147,400 sh
117,400 sh
391%
$4,634
$4,171
Eam Investors
140,768 sh
140,768 sh
NEW
$4,426
$4,426
Invesco.
137,389 sh
-33,838 sh
-20%
$4,319
$1,721
Royce & Associates Lp
114,000 sh
43,584 sh
62%
$3,584
$2,516
Morgan Stanley
109,640 sh
50,946 sh
87%
$3,447
$2,556
Northernrp
95,197 sh
4,646 sh
5%
$2,993
$1,619
Mairs & Power
91,903 sh
-74,670 sh
-45%
$2,889
$362
COMPANY PROFILE
1. Business organization CVRx, Inc. (the “Company”) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. The Company has developed and is marketing a medical device, Barostim, for heart failure (“HF”) and resistant hypertension. The Company is focused on the sale of its product in the U.S. and Europe. Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that the Company will generate sufficient product sales to produce positive earnings or cash flows.

Free historical financial statements for CVRx Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 11 quarters since 2021. Compare with CVRX stock chart to see long term trends.

Data imported from CVRx Inc. SEC filings. Check original filings before making any investment decision.